secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001804220-22-000013
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q1 revenue up 17% to $2.97B; non-GAAP EPS $11.49, GAAP EPS $8.61; Dupixent +43%
--------------------------------------------------------------------------------

- Total revenue $2.97B (+17% YoY); ex-REGEN-COV revenue +25%; GAAP net income $974M, diluted EPS $8.61.
- Non-GAAP net income $1.32B, diluted EPS $11.49 (+16% YoY); free cash flow $1.96B.
- EYLEA U.S. net sales $1.52B (+13%); Dupixent global net sales $1.81B (+43% as recorded by Sanofi).
- R&D guidance raised to $3.27-$3.50B (GAAP), $2.90-$3.10B (non-GAAP); SG&A guidance unchanged.
- REGEN-COV inventory write-offs $58M in COGS; $211M unrealized losses on equity securities; EUA revised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422022000013/0001804220-22-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422022000013/regn-20220504.htm
  HTML page:      https://secwatch.observer/filing/0001804220-22-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer